Rick Heinick

Chairman, TearClear


Rick is an active board member, investor, and entrepreneur in ophthalmic pharmaceutical and medical device companies. He has served as Chairman and Founder of TearClear since early 2016. TearClear is a specialty ophthalmic pharmaceutical company with a family of products developed to deliver preservative-free drugs from preserved multi-dose bottles. Rick is a board member of Lentechs, a company developing a disruptive presbyopic and toric lens.

Rick has been CEO of Amydis Diagnostics, a biotech developing a diagnostic for Alzheimer’s through the retina. He was CEO of RxSight/Calhoun Vision, a company developing a revolutionary light adjustable intraocular lens. Previously he served as Executive Vice President at Bausch + Lomb. He was a board member of the Association of the Blind and Visually Impaired (ABVI) and a contributor to the Lions Club helping to raise money to treat pediatric cataracts.

Rick co-authored “The Merger Dividend,” published in Harvard Business Review. He has been featured in Bloomberg Businessweek, Chief Executive Magazine, and Pharmaceutical Executive. Rick holds a Bachelor’s degree from Boston University, and a Master of Management from McGill University.